Étiquette : psychiatrie

Psychedelic science in post-COVID-19 psychiatry, J. R. Kelly et al., 2020

Psychedelic science in post-COVID-19 psychiatry J. R. Kelly, M. T. Crockett, L. Alexander, M. Haran, A. Baker, L. Burke, C. Brennan and V. O’Keane Irish Journal of Psychological Medicine, 2020, 1-6. doi:10.1017/ipm.2020.94   The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are pre- dicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition [...]

Lire la suite

Psychedelic psychiatry’s brave new world, Nutt, D., Erritzoe, D., & Carhart-Harris, R., 2020

Psychedelic psychiatry’s brave new world. Nutt, D., Erritzoe, D., & Carhart-Harris, R. Cell, 2020, 181, (1), 24-28. Doi : 10.1016/j.cell.2020.03.020   After a legally mandated, decades-long global arrest of research on psychedelic drugs, investiga- tion of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction.   Introduction—Why the Psychedelic Revolution in Psychiatry? Research leading to the discovery of new pharmacological treatments for psychiat- ric disorders has been painfully slow. With a few exceptions, including the use of orexin [...]

Lire la suite

Hallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine, Danilo De Gregorio et al., 2021

Hallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine Danilo De Gregorio, Argel Aguilar-Valles, Katrin H. Preller, Boris Dov Heifets, Meghan Hibicke, Jennifer Mitchell, and Gabriella Gobbi The Journal of Neuroscience,  2021, 41 (5), 891–900. Doi :10.1523/JNEUROSCI.1659-20.2020   A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of psychiatric disorders. In the last decade, a plethora of preclinical and clinical studies have confirmed the efficacy of ketamine in the treatment of depression. More recently, emerging evidence has pointed out the potential therapeutic properties of psilocybin and LSD, as well as [...]

Lire la suite

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy, Kate Corrigan et al., 2021

Psychedelic perceptions: mental health service user attitudes to psilocybin therapy Kate Corrigan · Maeve Haran · Conor McCandliss · Roisin McManus · Shannon Cleary · Rebecca Trant · Yazeed Kelly · Kathryn Ledden · Gavin Rush · Veronica O’Keane · John R. Kelly Irish Journal of Medical Science (1971 -), 2021, 1-13. Doi : 10.1007/s11845-021-02668-2   Abstract Introduction : Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes. Objectives : To explore mental health service user attitudes to psychedelics and psilocybin therapy. Methods : A questionnaire capturing demographics, diagnoses, previous [...]

Lire la suite

EDITORIAL : Cannabinoids in psychiatry : they are here to stay, Julia Jiyeon Woo et al., 2022

EDITORIAL : Cannabinoids in psychiatry : they are here to stay Julia Jiyeon Woo, Emma van Reekum, Sagnik Bhattacharyya and Zainab Samaan The British Journal of Psychiatry, 2022, 1-3. doi : 10.1192/bjp.2021.216   Summary Cannabinoids are commonly perceived by the public as safe and effective for improving mental health, despite limited evidence to support their use. We discuss reasons why cannabinoids may be particularly compelling for our patients and provide strategies for how psychiatrists can counsel and educate patients on the evidence regarding cannabinoids. Keywords : Cannabis; drug interactions and side-effects; drugs of dependence disorders; marijuana; education and training.   Vignette A young man sits in his psychiatrist’s office. After [...]

Lire la suite

Cannabinoid-based Medications for Pain Raymond M. St. Marie, Raphael J. Leo, 2021

Cannabinoid-based Medications for Pain Raymond M. St. Marie, MD; Raphael J. Leo, MA, MD Current Psychiatry, 2021, 20(5), 21-33. Abstract and Introduction Introduction Against the backdrop of an increasing opioid use epidemic and a marked acceleration of prescription opioid–related deaths,[1,2] there has been an impetus to explore the usefulness of alternative and co-analgesic agents to assist patients with chronic pain. Preclinical studies employing animal-based models of human pain syndromes have demonstrated that cannabis and chemicals derived from cannabis extracts may mitigate several pain conditions.[3] Because there are significant comorbidities between psychiatric disorders and chronic pain, psychiatrists are likely to care for patients with chronic pain. As [...]

Lire la suite

Low-Dose Nitrous Oxide Shows Benefit for Resistant Depression, Batya Swift Yasgur, Medscape.com, 2021

Low-Dose Nitrous Oxide Shows Benefit for Resistant Depression Batya Swift Yasgur, MA, LSW Medscape.com, 2021 June 17, 2021 A 1-hour treatment with a low concentration of nitrous oxide, commonly known as "laughing gas," appears to relieve symptoms of treatment-resistant major depression (TRMD), with effects lasting as long as several weeks, new research suggests. In a trial with a crossover design, investigators randomly assigned 28 patients with severe TRMD to receive a single 1-hour inhalation of placebo or nitrous oxide once a month over a 3-month period. Participants received an inhalation of placebo; a 25% concentration of nitrous oxide; and a 50% concentration of nitrous oxide. Sessions were [...]

Lire la suite

The Impact of Cannabidiol on Psychiatric and Medical Conditions, Thersilla Oberbarnscheidt & Norman S. Miller, 2019

The Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159   Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]

Lire la suite

http://latelelibre.fr/reportages/cannabis-service-de-psychiatrie/

http://latelelibre.fr/reportages/cannabis-service-de-psychiatrie/ Le Cannabis au Service de la Psychiatrie Publié le 5 mars 2021 | par La Rédac' [CANNABIS CONNECTION /S1-E7] Depuis 40 ans de carrière, le pédopsychiatre Christian Sueur poursuit son combat : faire savoir que le cannabis est une drogue qui peut être l’amie de l’homme. Pour ses vertus thérapeutiques, mais aussi festives et sacrées. Avec lui, nous découvrons aussi que la prohibition du cannabis est née aux USA, sur des préjugés racistes.   Celui que nous allons rencontrer aujourd’hui, dans les premières collines, au sud du Massif Central, est un des psychiatres français les plus connus et les plus engagés dans la recherche [...]

Lire la suite

Marginalisation, stigmatisation et abandon du LSD en médecine, Zoë Dubus, 2019

Marginalisation, stigmatisation et abandon du LSD en médecine Zoë Dubus Histoire, médecine et santé, 2019, 15, 87-105 Doi : 10.4000/hms.2168 https://journals.openedition.org/hms/2168 Abstracts Après avoir été l’une des substances pharmacologiques les plus étudiées des années 1950-1970, le LSD, puissant psychédélique ayant de nombreuses indications thérapeutiques, est abandonné par la communauté scientifique internationale au début des années 1970. Si des facteurs externes à la médecine ont eu un impact sur le déclin de ce médicament, il est également nécessaire de s’interroger sur les causes internes de ce rejet. Pour ce faire, une littérature anglo-saxonne émerge ces dernières années dans le champ des psychedelic studies, que nous enrichissons ici par une [...]

Lire la suite